Nakfa Hospital, Ministry of Health Northern Red Sea Branch, Nakfa, Eritrea.
Orotta School of Medicine, Orotta College of Medicine and Health Sciences, Asmara, Eritrea.
PLoS One. 2023 Mar 9;18(3):e0282642. doi: 10.1371/journal.pone.0282642. eCollection 2023.
Treatment failure (TF) in HIV infected children is a major concern in resource-constrained settings in Sub-Saharan Africa (SSA). This study investigated the prevalence, incidence, and factors associated with first-line cART failure using the virologic (plasma viral load), immunologic and clinical criteria among HIV-infected children.
A retrospective cohort study of children (<18 years of age on treatment for a period of > 6 months) enrolled in the pediatric HIV/AIDs treatment program at Orotta National Pediatric Referral Hospital from January 2005 to December 2020 was conducted. Data were summarized using percentages, medians (± interquartile range (IQR)), or mean ± standard deviation (SD). Where appropriate, Pearson Chi-Squire (χ2) tests or Fishers exacts test, Kaplan-Meier (KM) estimates, and unadjusted and adjusted Cox-proportional hazard regression models were employed.
Out of 724 children with at least 24 weeks' follow-up 279 experienced therapy failure (TF) making prevalence of 38.5% (95% CI 35-42.2) over a median follow-up of 72 months (IQR, 49-112 months), with a crude incidence of failure of 6.5 events per 100- person-years (95% CI 5.8-7.3). In the adjusted Cox proportional hazards model, independent factors of TF were suboptimal adherence (Adjusted Hazard Ratio (aHR) = 2.9, 95% CI 2.2-3.9, p < 0.001), cART backbone other than Zidovudine and Lamivudine (aHR = 1.6, 95% CI 1.1-2.2, p = 0.01), severe immunosuppression (aHR = 1.5, 95% CI 1-2.4, p = 0.04), wasting or weight for height z-score < -2 (aHR = 1.5, 95% CI 1.1-2.1, p = 0.02), late cART initiation calendar years (aHR = 1.15, 95% CI 1.1-1.3, p < 0.001), and older age at cART initiation (aHR = 1.01, 95% CI 1-1.02, p < 0.001).
Seven in one hundred children on first-line cART are likely to develop TF every year. To address this problem, access to viral load tests, adherence support, integration nutritional care into the clinic, and research on factors associated with suboptimal adherence should be prioritized.
在撒哈拉以南非洲(SSA)资源有限的环境中,艾滋病毒感染儿童的治疗失败(TF)是一个主要问题。本研究使用病毒学(血浆病毒载量)、免疫学和临床标准,调查了接受一线抗逆转录病毒治疗(cART)的艾滋病毒感染儿童中首次 cART 失败的流行率、发生率和相关因素。
对 2005 年 1 月至 2020 年 12 月期间在 Orotta 国家儿科转诊医院接受儿科艾滋病毒/艾滋病治疗方案治疗超过 6 个月的儿童(年龄<18 岁)进行了回顾性队列研究。使用百分比、中位数(±四分位距(IQR))或平均值±标准偏差(SD)来总结数据。在适当的情况下,使用 Pearson Chi-Squire(χ2)检验或 Fisher 精确检验、Kaplan-Meier(KM)估计以及未调整和调整后的 Cox 比例风险回归模型。
在至少有 24 周随访的 724 名儿童中,279 名经历了治疗失败(TF),TF 的患病率为 38.5%(95%CI 35-42.2),中位随访时间为 72 个月(IQR 49-112 个月),未调整的失败发生率为每 100-人年 6.5 例(95%CI 5.8-7.3)。在调整后的 Cox 比例风险模型中,TF 的独立因素是不适当的依从性(调整后的危险比(aHR)=2.9,95%CI 2.2-3.9,p<0.001)、齐多夫定和拉米夫定以外的 cART 骨干药物(aHR=1.6,95%CI 1.1-2.2,p=0.01)、严重免疫抑制(aHR=1.5,95%CI 1-2.4,p=0.04)、消瘦或体重身高 z 分数<−2(aHR=1.5,95%CI 1.1-2.1,p=0.02)、cART 开始的晚年份(aHR=1.15,95%CI 1.1-1.3,p<0.001)和 cART 开始时的年龄较大(aHR=1.01,95%CI 1-1.02,p<0.001)。
每一百名接受一线 cART 的儿童中,就有七名可能每年都会发生 TF。为了解决这个问题,应优先考虑获得病毒载量检测、支持依从性、将营养护理纳入诊所,以及研究与不适当依从性相关的因素。